CM
KNSA icon

Castleark Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Castleark Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Sell
174,032
-7,480
-4% -$388K 0.3% 70
2026
Q1 		$8.74M Sell
181,512
-10,680
-6% -$473K 0.29% 74
2025
Q4 		$7.93M Buy
192,192
+33,560
+21% +$1.35M 0.23% 99
2025
Q3 		$6.16M Buy
+158,632
New +$5.15M 0.17% 132
2024
Q4 		– Sell
-167,200
Closed -$4.18M – 307
2024
Q3 		$4.18M Buy
+167,200
New +$4.07M 0.17% 134

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Castleark Management's KNSA Position: Q2 2026 in Review

Castleark Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 4.1% in Q2 2026, selling an estimated $388K and leaving 174,032 shares worth $11.1M. The position accounts for 0.3% of the portfolio, ranked #70.

Castleark Management first reported a position in KNSA in Q3 2024 and has held it in 5 quarters since. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Castleark Management held 174,032 shares of Kiniksa Pharmaceuticals worth $11.1M as of Q2 2026.
  • Castleark Management sold 7,480 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $388K.
  • Kiniksa Pharmaceuticals made up 0.3% of Castleark Management's portfolio in Q2 2026, its #70 holding.
  • Castleark Management first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.